Meeting
2021 Genitourinary Cancers Symposium
Novel synthetic lethality (SL) anti-cancer drug target in urothelial bladder cancer (UCB) based on MTAP genomic loss: Incidence and correlations in standard of care (SOC).
Authors
Gennady Bratslavsky
SUNY Upstate University Hospital, Bethesda, MD
Gennady Bratslavsky , Joseph M Jacob , Andrea Necchi , Petros Grivas , Natalie Danziger , Ethan Sokol , Russell Madison , Shakti H. Ramkissoon , Ryon Graf , Douglas A Mata , Brennan James Decker , Jeffrey S. Ross
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 485)
DOI
10.1200/JCO.2021.39.6_suppl.485
Abstract #
485
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Landscape of fibroblast growth factor receptor (FGFR) genomic alterations (GA) in urothelial bladder cancer (UBC).
First Author: Maroun Bou Zerdan
Poster
2023 ASCO Annual Meeting
Penile squamous cell carcinoma (PSCC) with elevated tumor mutational burden (TMB): A genomic landscape study.
First Author: Rebecca A Sager
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile.
First Author: Petros Grivas
Poster
2021 ASCO Annual Meeting
Genomic landscape of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase (MTAP) deletion.
First Author: Stephen L. Graziano